Piper Jaffray analyst William Quirk reiterated an Overweight rating and lifted his price target on TrovaGene (NASDAQ: TROV) to $7.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE